September 6, 2007 - Iomai Corp. said it began dosing in a Phase 1/2 study to assess the safety and dose-sparing capability of the company's immunostimulant patch when used in combination with an injected H5N1 influenza vaccine.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now